Axillary Management After Neoadjuvant Therapy for Triple-Negative Breast Cancer
A 43-year-old premenopausal woman has a 2.4-cm triple-negative invasive ductal carcinoma of the right breast and one biopsy-proven right axillary node, with a clip placed in that node. She completed six cycles of neoadjuvant docetaxel–carboplatin–pembrolizumab. MRI now shows a 1.1-cm residual breast mass and a normal-appearing axilla. She wants breast conservation and asks whether she can avoid an axillary dissection. Genetic testing is pending; she has no family history. The breast surgeon confirms that lumpectomy with oncoplastic closure and whole-breast radiation is feasible.
1. How should the axilla be managed at surgery, and what would you do if the clipped node is not identified?
Read the worked answer
Proceed with targeted axillary dissection: remove the clipped node and the sentinel nodes, using dual tracer and, if needed, a radioactive seed or wire to locate the clip. This is appropriate because the axilla was node-positive at diagnosis and she received neoadjuvant therapy. If the clipped node and all sentinel nodes are negative, she can avoid axillary lymph node dissection; the false-negative rate is lowest when the clipped node is removed and at least three sentinel nodes are examined. If the clipped node cannot be found, do not assume it is negative-convert to axillary dissection or re-localize it. If any node contains residual disease, completion axillary dissection is generally indicated, though nodal radiation is an alternative in selected patients. Document the findings to guide radiation.
2. Final pathology shows an 8-mm residual focus in the clipped node and 1/4 sentinel nodes positive, with clear margins. What is your axillary and adjuvant plan?
Read the worked answer
Residual nodal disease after neoadjuvant chemotherapy changes the plan. She should undergo completion axillary lymph node dissection, because the trial data supporting avoidance of dissection apply to patients who become node-negative, not to those with residual nodal disease. Axillary radiation may be considered as an alternative or adjunct in a multidisciplinary discussion, particularly if the dissection would be morbid. For triple-negative breast cancer with residual invasive disease after neoadjuvant chemotherapy, adjuvant capecitabine improves survival and should be discussed; continue adjuvant pembrolizumab per the regimen she received. Breast conservation is still reasonable if margins are clear, followed by whole-breast radiation. Genetic testing results will influence contralateral risk-reducing surgery and family counseling.
3. She asks why she cannot simply have a lumpectomy without radiation. How do you counsel her?
Read the worked answer
Explain that lumpectomy alone would leave a substantial residual risk of local recurrence, especially with triple-negative biology, young age, and residual disease after chemotherapy. Whole-breast radiation after lumpectomy reduces local recurrence and is standard; omitting it is not supported outside a clinical trial. If she strongly wishes to avoid radiation, mastectomy is the alternative, but it is a larger operation and may still require postmastectomy radiation if risk factors are present. Radiation also has risks-skin reaction, fatigue, rare cardiac or pulmonary effects-so the discussion is a balance. The decision should be shared, but she should understand that less surgery does not mean no local therapy.